Immunosuppression Boost With Mycophenolate Mofetil for Mixed Chimerism in Thalassemia Transplants

Area of Science:

• Hematology
• Immunology
• Transplantation Science

Background:

• Declining mixed chimerism (MC) after hematopoietic stem cell transplantation (HSCT) can indicate graft failure.
• Hemoglobinopathies in a stable MC state often persist without rejection in 30-40% of patients.
• Early detection and monitoring of MC levels are significant for predicting transplant outcomes.

Purpose of the Study:

• To evaluate the outcomes of mixed chimerism in transfusion-dependent thalassemia patients post-HSCT.
• To compare the efficacy of an immunosuppression boost strategy versus conventional immunosuppression tapering for managing MC.

Main Methods:

• Retrospective evaluation of 90 transfusion-dependent thalassemia patients undergoing HSCT between September 2013 and January 2022.
• Analysis of MC status and management strategies, including immunosuppression withdrawal versus boost.
• Comparison of outcomes such as complete chimerism, persistent MC, and secondary rejection between the two groups.

Main Results:

• Among 22 patients with MC, 12 underwent immunosuppression withdrawal, resulting in 2 complete chimerisms, 5 persistent MCs, and 5 secondary rejections.
• Eight patients received an immunosuppression boost, all maintaining persistent MC with no secondary rejection during the median follow-up.
• Secondary rejections in the withdrawal group occurred at a median of 186 days post-transplant.

Conclusions:

• An immunosuppression boost approach may be beneficial in maintaining stable mixed chimerism and preventing graft rejection in thalassemia patients post-HSCT.
• Further research with larger cohorts is needed to establish the statistical significance of the immunosuppression boost strategy compared to conventional tapering.